胰腺导管腺癌的分子特征分析研究进展。
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma.
机构信息
Department of Surgery, University of North Carolina at Chapel Hill, 170 Manning Dr, CB7213, Chapel Hill, NC 27599-7213, USA.
Department of Surgery, University of North Carolina at Chapel Hill, 170 Manning Dr, CB7213, Chapel Hill, NC 27599-7213, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, NC 27599-7295, USA.
出版信息
Surg Clin North Am. 2024 Oct;104(5):939-950. doi: 10.1016/j.suc.2024.04.001. Epub 2024 May 16.
Outcomes from pancreatic ductal adenocarcinoma (PDAC) remain poor and better methods of prognostication and therapeutic approaches are needed. Recent advances in cancer genomics have led to the development of molecular subtypes of PDAC associated with clinical outcomes. Current evidence also suggests that the subtypes have differential response to first-line chemotherapy regimens. PDAC is also characterized by different stroma and immune environments. Further work is needed to confirm the utility of these subtypes to predicting response to different systemic therapies.
胰腺导管腺癌 (PDAC) 的治疗效果仍然不佳，需要更好的预后预测和治疗方法。癌症基因组学的最新进展导致了与临床结果相关的 PDAC 分子亚型的发展。目前的证据还表明，这些亚型对一线化疗方案有不同的反应。PDAC 还具有不同的基质和免疫环境。需要进一步的工作来确认这些亚型对预测不同系统治疗反应的效用。
Zotero 插件